Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorInstitute of Hematology & Blood Diseases Hospital, China

About this trial

Anemia is a global public health concern and is closely linked to dysfunction of brain cognitive neural networks, a key mechanism underlying cognitive impairment. Such deficits-including declines in memory, learning, processing speed, and executive function-reduce daily living abilities and increase risks of falls and depression.

Functional near-infrared spectroscopy (fNIRS) enables real-time monitoring of oxygenated and deoxygenated hemoglobin fluctuations, reflecting brain network function. This study aims to identify affected neural network regions in anemic patients and visualize connectivity changes using heatmaps and arc-based mapping. The findings will support early detection of cognitive impairment and guide precise clinical interventions, ultimately informing individualized treatment strategies to enhance therapeutic outcomes and quality of life.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of anemia

First hospitalization

Male or female, aged 18-65 years

Willing and able to comply with the requirements for this study and written informed consent

Disqualifiers

History of psychiatric illness

History of severe brain disease

Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study

Trial population

Patients with anemia who were hospitalized for the first time during the period from 2026 to 2028.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Concentration changes in oxygenated hemoglobin (HbO) and de-oxygenated hemoglobin (HbR)

Functional Near Infrared Spectroscopy (fNIRS) is a non-invasive brain imaging modality, that can be used to measure HbO and HbR concentrations.

Time frame
Patients will be assessed within 48 hours of admission.
2

Cognitive Function Assessment

Montreal Cognitive Assessment (MoCA) is used to assess cognitive function in patients, with higher total scores indicating better cognitive function. The total score range is 0 to 30.

Time frame
Patients will be assessed within 48 hours of admission.

Secondary outcomes

1

Anxiety symptoms

Hamilton anxiety scale(HAMA) is used to examine anxiety in AIHA patients, with higher total scores indicate more severe anxiety symptoms. The total score range is 0-56.

Time frame
Patients will be assessed within 48 hours of admission.
2

Depression symptoms

Hamilton depression scale(HAMD) is used to examine depression in AIHA patients, with higher total scores indicate more severe depression symptoms. The total score range is 0-52.

Time frame
Patients will be assessed within 48 hours of admission.
3

Sleep quality

The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality, with a higher global score indicating poorer sleep quality. The global score range is 0-21.

Time frame
Patients will be assessed within 48 hours of admission.
4

Physical fatigue

It measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale. The total possible score is 0-52 points, with higher scores indicating less fatigue.

Time frame
Patients will be assessed within 48 hours of admission.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.